| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Health Canada Approves Concentrated Version of Alpha1-Proteinase Inhibitor NEW YORK -- February 17, 2010 -- Health Canada has approved a more purified and concentrated version of Alpha1-Proteinase Inhibitor (Human; Prolastin-C) for the treatment of panacinar emphysema in patients with alpha1-antitrypsin (AAT) deficiency. The concentrated version, which will replace the original version, delivers twice the active protein per millilitre, cutting infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min. Clinical studies have shown that Prolastin-C and Prolastin are equally effective at raising AAT levels in the blood. In clinical trials, the most common drug-related adverse reactions observed at a rate of >= 1% in patients receiving Prolastin-C were chills, malaise, headache, rash, hot flush, and pruritus. The manufacturer, Talecris Biotherapeutics, will provide information about the transition from Prolastin to Prolastin-C through the product’s distribution program and through pharmacies that assist physicians and their patients who currently receive Prolastin therapy. SOURCE: Talecris Biotherapeutics
|